Thursday, September 17, 2026
| 09:00 - 10:30 |
Session 1: RLT - the preclinical pipeline
Speaker:
- Renata Mikolajczak: Which radionuclides do we need for theranostics
- TBA: New Infrastructure in Austria - Graz
- Markus Mitterhauser: New Infrastructure in Austria - Vienna
- Clemens Decristoforo: New Infrastructure in Austria - Innsbruck
|
| 10:30 - 11:00 |
Coffee Break |
| 11:00 - 12:45 |
Session 2: RLT - the preclinical pipeline
Speaker:
- Uta Eberlein: The importance of Radiobiology in RLT
- Mattias Sandström: 3D Dosimetry
Oral Abstracts - Preclinical
- Jakob Pfeiffer-Vogl: Assessing the interaction of ciprofloxacin with membrane transporters by combined PET and in vitro transport studies
- Maximilian Anderla: Unlocking the Potential of Ruthenium Radioisotopes for Radiopharmaceutical Development
- Matthias Jackwerth: 6-Bromo-7-[11C]methylpurine as a novel PET tracer to assess cellular defense against oxidative stress in the human brain
- Emanuel Sporer: Establishment of Actinium-225 radiopharmaceutical production at the Medical University of Innsbruck
|
| 13:00 - 14:00 |
Industry Lunch Symposium |
| 14:00 - 15:30 |
Session 3: RLT - the clinical pipeline
Speaker:
- Elisabeth von Guggenberg: Update on the clinical translation of cholecystokinin-2 receptor targeted theranostics
- Constantin Lapa: FAP-targeting
- Serge Lyashchenko: Clinical Trials in the US- examples from MSKCC
|
| 15:30 - 16:00 |
Coffee Break |
| 16:00 - 17:30 |
Session 4: Improvements in technology - does it change clinical practice
Speaker:
- Christos Sachpekidis: Whole body PET - does it change clinical management
Oral Abstracts - Mixed Rapid Fire:
- Gregor Schweighofer-Zwink: Bridging the workforce gap? Current use and implementation barriers of AI in Austrian nuclear medicine
- Elisabeth von Guggenberg; Optimization of the radiolabelling process for cholecystokinin-2 receptor targeting DOTA-MGS5 labelled with gallium-68 and lutetium-177
- Ramin Tahmasebi: External radiation exposure in 177Lu-based radioligand therapy
- Martin Kraihammer: Comparison of automated synthesis of radiopharmaceuticals for radioligand therapy with versus without C-18 purification
- Lukas Pichler: 18F-FDG PET/CT as a diagnostic landmark in a case of multifocal atypical primary bone lymphomas
- Petra Gröger: A novel approach for correcting the residual radiotracer activity concentration at the injection site
- Claas Duit: Quantification of Radiation Dose Reduction for Radiologic Technologists through the Use of Automated Injection Systems for FDG-PET in Austria
|
| 17:30 - 18:00 |
Coffee Break |
| 18:00 - 19:00 |
Session 5: Fireside Session: Debate
Speaker:
- Irene Virgolini + Team: Dosimetry - to dose or not to dose in clinical practice - pro
- TBA: Dosimetry - to dose or not to dose in clinical practice - con
|
Friday, September 18, 2026
| 09:00 - 10:30 |
Session 6: RLT the clinical blockbusther: Prostate
Speaker:
- Ursula Vogl: The oncologist's perspective
- Christian Pirich: How it's done in clinical practice
- Karolien Goffin: Novel approches - is there room for improvement
|
| 10:30 - 11:00 |
Coffee Break |
| 11:00 - 12:45 |
Session 7: Improvements in technology - does it change clinical practice
Speaker:
- Wolfgang Schäfer: CZT for Cardiac SPECT - is quantification real
- Laszlo Papp: Marrying Nuclear Medicine and (Quantum) AI for advancing patient care
Oral Abstracts - Clinical
- Lisa-Maria Rossetti: Hybrid imaging with the innovative PET-tracer 68Ga-ABS011 in HER2-low metastatic breast and gynaecological cancer
- Holger Einspieler: [177Lu]Lu-PSMA-I&T radioligand therapy in hormone-sensitive prostate cancer with biochemical recurrence: interim clinical outcomes from a prospective trial
- Gregor Schweighofer-Zwink: Baseline [18F]FDG PET/CT Predicts Response to Neoadjuvant Immunochemotherapy in HER2-Positive Early Breast Cancer: A Substudy of the ABCSG-52/ATHENE Trial
- Teresa Kiener: Can [68Ga]PSMA-PET/CT Guide Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer?
|
| 13:00 - 14:00 |
Industry Lunch Symposium |
| 14:00 - 15:30 |
Session 8: Perspective of young professionals in our field
Speaker:
- Michael Kellner: Nuclear Medicine
- Elisabeth Plhak: Radiopharmacy
- Sabine Weissensteiner: NM Technologists
- Emanuel Sporer: Radiochemistry
- Flora Kaser: Medical Physics
- Margret Schottelius: EANM perspective
|
| 15:30 - 16:00 |
Coffee Break |
| 16:00 - 17:10 |
Session 9: Distinguished Pioneer Lecture
Speaker:
- John Babich: The Evolution of Radiopharmaceuticals: From Radioiodine to Modern Radioligand Therapy
|
| 19:00 |
Social Evening (separate ticket required)
at Kaiserliche Stallungen Bad Ischl
|
Saturday, September 19, 2026
| 09:00 - 10:30 |
Session 10: Thyroid Session
Speaker:
- Lindsay Hargitai: Surgical treatment strategies for advanced differentiated thyroid cancer
- Markus Luster: Systemic therapy in advanced differentiated throid cancer
- Michael Gabriel: Theranostic approaches beyond I-131 in advanced differentiated thyroid cancer
|
| 10:30 - 11:00 |
Coffee Break |
| 11:00 - 12:30 |
Session 11
Speaker:
- Johannes Sebastian Gnörich: PET Imaging of Dementia – a Tool for Patient Management Now and in the Future
- Tandis Parvizi: New anti-Alzheimer's drugs – Status Quo and Future Aspects – An Austrian Perspective
|
